AbbVie Inc. (BCBA:ABBV)

Market Cap	382.38T
Revenue (ttm)	61.56T
Net Income (ttm)	4.46T
Shares Out	n/a
EPS (ttm)	2,510.97
PE Ratio	85.76
Forward PE	14.30
Dividend	417.13 (1.89%)
Ex-Dividend Date	Apr 15, 2025

Volume	1,142
Average Volume	2,649
Open	22,450
Previous Close	22,450
Day's Range	21,975 - 22,525
52-Week Range	18,325 - 27,925
Beta	n/a
RSI	48.65
Earnings Date	Jul 25, 2025

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2012
• Employees: 55,000
• Stock Exchange: Buenos Aires Stock Exchange
• Ticker Symbol: ABBV

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD